Valli M, Pringuey D
Therapie. 1980 Sep-Oct;35(5):561-9.
The benzodiazepines (BZD) are widely used in clinical practice as anxiolytics, muscle relaxants, sedatives and anticonvulsants. Electrophysiological studies have shown a specific interaction of BZD with - aminobutyric acid (GABA), an inhibitory neurotransmitter, of which they enhance the physiological effects. The discovery of saturable and stereospecific binding sites with high affinity for BZD, and their brain distribution indicates a predominantly cortical action of BZD. Furthermore, BZD receptors seem to be linked to GABA receptors--modulating their inhibitory effects--and closely connected to the chloride conductance mechanism associated to the GABA receptor. The discovery of BZD receptors suggests the existence of endogenous ligands. Inosine, hypoxanthine or nicotinamide are reported to have BZD-like activities, in spite of a relative low affinity for their binding sites. Their putative role as endogenous anxiolytics needs to be supported by behavioral studies.
苯二氮䓬类药物(BZD)在临床实践中被广泛用作抗焦虑药、肌肉松弛剂、镇静剂和抗惊厥药。电生理研究表明,BZD与抑制性神经递质γ-氨基丁酸(GABA)存在特异性相互作用,可增强其生理效应。对BZD具有高亲和力的可饱和性和立体特异性结合位点的发现及其在脑内的分布表明,BZD主要作用于皮质。此外,BZD受体似乎与GABA受体相连——调节其抑制作用——并与GABA受体相关的氯电导机制紧密相连。BZD受体的发现提示内源性配体的存在。据报道,肌苷、次黄嘌呤或烟酰胺具有类BZD活性,尽管它们与其结合位点的亲和力相对较低。它们作为内源性抗焦虑药的假定作用需要行为学研究的支持。